nearli
licens
vaccin
confer
protect
infecti
diseas
stimul
product
pathogenspecif
ab
b
cell
understand
natur
success
ab
respons
therefor
fundament
step
provid
new
tool
design
novel
better
vaccin
isol
character
ab
repertoir
produc
antigenspecif
b
cell
acquir
central
import
last
decad
unravel
respons
vaccin
antigen
dissect
basic
mechan
defin
dynam
ab
respons
vaccin
deepen
knowledg
correl
vaccineinduc
protect
biolog
signatur
respons
becom
fundament
develop
novel
vaccin
memori
b
cell
mbc
plasmablast
peak
day
vaccin
use
gener
natur
deriv
antigenspecif
mab
mbc
shown
suitabl
kind
applic
capabl
secret
ab
ebv
immort
presenc
ligand
andor
allogen
irradi
mononuclear
cell
traggiai
et
al
usual
total
peripher
blood
lymphocyt
sort
igg
mbc
cultur
releas
ab
screen
antigen
specif
andor
function
recent
discov
even
singl
plasmablast
cultur
without
immort
produc
suffici
amount
ab
allow
screen
ab
specif
function
jin
et
al
corti
et
al
approach
particularli
success
isol
nab
individu
infect
rapidli
evolv
viral
pathogen
lead
identif
new
target
molecul
induc
potent
broadli
neutral
respons
without
prior
knowledg
natur
power
character
ab
produc
human
b
cell
gener
vivo
respons
specif
infect
prove
far
differ
virus
influenza
hcmv
dengu
rsv
beltramello
et
al
corti
et
al
macagno
et
al
kraus
et
al
de
alwi
et
al
two
emblemat
exampl
human
mab
valuabl
tool
discov
design
new
antigen
come
hcmv
rsv
studi
hcmv
focus
viral
glycoprotein
gb
ghgl
target
nab
screen
mab
immun
donor
base
capac
neutral
infect
vitro
panel
potent
nab
identifi
ab
recogn
multipl
antigen
site
pentamer
complex
previous
known
target
nab
macagno
et
al
followup
studi
pentamerbas
vaccin
report
elicit
high
nab
titer
mice
kabanova
et
al
provid
evid
power
revers
vaccinolog
approach
identif
design
improv
hcmv
vaccin
candid
furthermor
independ
structur
immunolog
studi
also
demonstr
antigen
potenti
hcmv
pentam
mice
wen
et
al
ciferri
et
al
second
exampl
come
analysi
nab
respons
f
protein
rsv
initi
postfus
f
protein
rsv
chosen
candid
develop
vaccin
stabl
protein
recogn
neutral
mab
palivizumab
use
prevent
rsv
infect
newborn
impactrsv
studi
group
howev
promis
altern
postfus
f
antigen
also
identifi
rsvspecif
human
b
cell
transduc
bclxl
use
sourc
identifi
ab
effect
neutral
viru
screen
b
cell
cultur
supernat
nab
call
time
potent
isol
shown
complet
prevent
viral
replic
vivo
rsv
infect
model
cotton
rat
kwakkenbo
et
al
subsequ
studi
shown
two
addit
highli
potent
rsvspecif
nab
specif
prefus
form
rsv
f
mclellan
et
al
furthermor
analyz
mani
differ
mab
isol
rsv
seroposit
individu
corti
et
al
also
shown
potent
nab
recogn
prefus
form
f
antigen
suggest
prefus
protein
could
consid
effect
vaccin
antigen
exampl
isol
character
bnab
induc
infect
highlight
understand
mechan
lead
elicit
protect
respons
aid
design
effect
vaccin
howev
identif
mab
desir
specif
usual
requir
interrog
thousand
b
cell
laborintens
cultur
screen
step
b
cell
cultur
supernat
lead
isol
dozen
ab
moreov
approach
allow
gain
substanti
inform
shape
ig
gene
repertoir
induc
respons
given
pathogen
vaccin
mileston
understand
natur
gener
success
ab
respons
develop
ab
repertoir
sequenc
technolog
identif
gener
recombin
human
mab
first
descript
singlecel
rtpcr
method
show
possibl
isol
ig
heavi
vh
light
vl
variabl
chain
gene
singl
b
cell
follow
express
chimer
murin
rabbit
mab
babcook
et
al
anoth
hallmark
field
human
immunolog
demonstr
clone
express
human
mab
could
achiev
recoveri
ig
sequenc
singl
b
cell
deriv
bone
marrow
blood
healthi
donor
transfect
produc
cell
vh
vl
chain
gene
wardemann
et
al
furthermor
possibl
use
fluoresc
label
antigen
sort
antigenspecif
b
cell
flow
cytometri
facilit
focus
analys
ig
gene
repertoir
usag
correspond
ab
bind
andor
function
capabl
toward
target
antigenspecif
often
rare
b
cell
subpopul
vaccin
infect
tiller
et
al
wrammert
et
al
scheid
et
al
although
methodolog
allow
sequenc
express
ab
encod
small
number
b
cell
individu
brought
numer
immunolog
insight
develop
b
cell
respons
antigen
differ
natur
exampl
demonstr
b
cell
respons
polysaccharid
streptococcu
pneumonia
polysaccharid
show
high
clonal
limit
ig
gene
usag
differ
divers
age
group
kolibab
et
al
smith
et
al
instead
greater
repertoir
divers
highlight
differ
individu
even
within
singl
individu
differ
time
point
vaccin
protein
antigen
influenza
hemagglutinin
ha
tetanu
toxoid
tt
wrammert
et
al
et
al
howev
mainli
research
hiv
field
demonstr
character
bnab
isol
immun
donor
knowledg
pathway
gener
provid
new
insight
induc
new
vaccin
strategi
novel
recombin
solubl
envelop
env
protein
use
bait
identifi
captur
env
b
cell
flow
cytometri
select
hivinfect
donor
scheid
et
al
wu
et
al
singlecel
ab
clone
techniqu
success
gener
hundr
hivspecif
ab
among
dozen
new
extrem
potent
nextgener
bnab
doriaros
connor
klein
et
al
burton
mascola
hayn
real
challeng
take
advantag
understand
gener
bnab
design
new
immunogen
abl
induc
affin
matur
b
cell
lineag
express
bnab
essenti
mean
abl
orchestr
finetun
interplay
host
immun
system
tailor
antigen
antigen
prime
b
cell
precursor
effect
way
discuss
section
vaccini
strategi
target
germlin
ab
aforement
method
two
limit
identif
best
protect
ab
first
requir
ebv
transform
b
cell
bia
secret
mab
second
synthet
ab
might
alway
faith
reflect
natur
function
capabl
overcom
limit
burtion
poignard
cowork
isol
hivspecif
human
mab
mbc
expand
vitro
addit
feeder
cell
condit
medium
gener
mitogenstimul
human
cell
screen
supernat
neutral
activ
walker
et
al
modifi
highthroughput
approach
also
recent
develop
base
isol
mbc
pbmc
expans
vitro
without
need
activ
cell
supernat
allow
secret
suffici
amount
ab
cultur
screen
bind
function
assay
huang
et
al
main
advantag
techniqu
provid
possibl
isol
directli
character
ab
produc
individu
clone
b
cell
without
need
clone
express
recombin
mab
importantli
maintain
origin
natur
properti
bind
function
character
bind
andor
function
capac
ab
ig
gene
sequenc
recov
turn
repertoir
analys
understand
origin
evolut
ab
interest
perform
clone
express
step
deeper
structur
character
perform
fig
recent
new
approach
broad
potent
hiv
nab
discov
pool
antigenspecif
mbc
highlight
new
vulner
site
hiv
env
antigen
huang
et
al
effici
new
methodolog
applic
preselect
antigenspecif
singlesort
mbc
b
cell
subpopul
unknown
specif
enabl
identif
new
target
antigen
epitop
involv
protect
ab
respons
fig
overal
singl
b
cell
clone
approach
use
isol
mab
demonstr
extrem
power
identif
character
key
protect
antigen
drawback
lowthroughput
technolog
reveal
limit
slice
full
ab
repertoir
therefor
use
techniqu
analyz
impact
vaccin
antigen
vaccin
formul
induc
specif
repertoir
signatur
share
differ
individu
may
lead
erron
mislead
conclus
recent
advanc
nextgener
sequenc
technolog
enabl
sequenc
ig
gene
million
b
cell
simultan
give
highresolut
character
ab
sequenc
repertoir
reddi
georgiou
nevertheless
abil
approach
recogn
antigenspecif
ab
repertoir
insid
total
individu
ab
repertoir
evalu
specif
chang
induc
vaccin
pathogen
still
remain
question
one
approach
comput
search
total
repertoir
data
ab
sequenc
share
among
individu
expos
antigen
infect
vaccin
identifi
converg
repertoir
three
recent
studi
found
conserv
sequenc
produc
patient
recov
acut
dengu
infect
parameswaran
et
al
immun
respons
pandem
influenza
vaccin
jackson
et
al
hibpolysaccharid
vaccin
et
al
although
converg
repertoir
demonstr
chang
largescal
structur
featur
repertoir
antigen
specif
identifi
ab
sequenc
alway
need
experiment
confirm
express
purif
function
test
recombin
ab
howev
small
subset
ab
usual
express
investig
exhaust
interrog
repertoir
miss
possibl
full
pictur
properti
function
ab
direct
one
specif
antigen
start
enrich
antigenspecif
b
cell
popul
studi
use
pbmc
isol
day
immun
peak
circul
plasmablast
yet
approach
entail
loss
inform
longitudin
evolut
b
cell
memori
repertoir
eventu
bnab
mainten
longterm
memori
popul
final
recent
studi
sequenc
pair
vhvl
ig
gene
repertoir
nextgener
sequenc
technolog
combin
novel
proteom
method
mine
antigenspecif
ab
repertoir
compris
human
serum
polyclon
respons
wine
et
al
new
perspect
offer
combin
analysi
b
cell
ab
repertoir
induc
tt
vaccin
highlight
antitt
serum
igg
repertoir
compos
limit
number
ab
clonotyp
wherea
b
cell
receptor
repertoir
divers
memori
plasmablast
compart
order
magnitud
greater
serolog
repertoir
lavind
et
al
observ
suggest
peripher
b
ab
unlik
present
detect
amount
solubl
protein
leav
unansw
question
regard
natur
dynam
element
regul
serolog
memori
collect
technolog
allow
dissect
human
ab
respons
pathogen
increas
understand
protect
induc
drive
design
efficaci
antigen
develop
vaccin
prevent
current
futur
pathogen
threat
incred
antigen
variabl
hiv
env
initi
led
belief
bnab
would
nearli
imposs
elicit
way
tackl
hiv
effici
would
gener
immun
howev
viewpoint
dramat
impact
landmark
discoveri
report
name
gener
two
new
recombin
mab
mab
combinatori
fab
phage
display
librari
burton
et
al
human
mab
isol
volunt
conley
et
al
shown
broadli
neutral
panel
hiv
strain
particular
mab
bind
conserv
bind
site
env
subunit
shown
neutral
primari
hiv
isol
test
burton
et
al
binley
et
al
howev
clear
limit
somewhat
low
potenc
mab
requir
neutral
hiv
strain
unit
state
moreov
mab
show
limit
effect
control
viremia
vivo
even
combin
distinct
bnab
similar
potenc
poignard
et
al
cardoso
et
al
recent
analys
neutral
divers
hiv
strain
walker
et
al
find
led
research
believ
abbas
therapi
vaccin
would
useless
hiv
control
develop
vaccin
base
env
compon
lost
momentum
hiv
field
chang
complet
around
identif
second
gener
bnab
first
use
neutral
screen
supernat
thousand
mbc
hivinfect
donor
two
potent
human
mab
target
broadli
neutral
epitop
describ
abl
neutral
test
hiv
strain
walker
et
al
use
antigenspecif
human
b
cell
sort
engin
probe
env
antigen
better
expos
conserv
epitop
power
new
bnab
eg
mab
group
call
target
conserv
env
subunit
identifi
one
found
abl
neutral
hiv
isol
overal
low
geometr
mean
wu
et
al
subsequ
abil
use
singlecel
technolog
allow
identif
sever
hundr
antihiv
human
mab
bnab
median
low
better
recombin
ab
isol
scheid
et
al
walker
et
al
burton
mascola
epitop
map
studi
use
new
ab
show
addit
origin
epitop
sever
region
hiv
env
abl
induc
bnab
new
ab
also
show
remark
therapeut
effect
vivo
rhesu
monkey
chronic
infect
pathogen
immunodefici
viru
abl
rapidli
reduc
plasma
viremia
undetect
level
keep
bay
month
barouch
et
al
similarli
therapeut
benefit
observ
suppress
viremia
shivinfect
macaqu
shingai
et
al
excitingli
one
therapeut
bnab
target
epitop
test
phase
clinic
trial
recent
report
reduc
plasma
viremia
chronic
infect
human
caskey
et
al
likewis
phase
studi
use
infus
class
ab
show
promis
result
reduc
plasma
viremia
suppress
neutralizationsensit
strain
subset
subject
lynch
et
al
new
find
describ
previou
paragraph
may
complet
chang
approach
hiv
prevent
therapi
today
abmedi
protect
believ
promis
approach
hiv
control
immunolog
structur
inform
avail
use
design
vaccin
antigen
notabl
includ
emerg
class
recombin
env
sosip
solubl
stabil
disulphid
bridg
ile
pro
mutat
immunogen
stabil
nativelik
conform
abl
induc
nab
neutralizationresist
tier
hiv
rabbit
lesser
extent
macaqu
sander
et
al
altern
inform
could
use
produc
cocktail
therapeut
ab
deliv
simultan
passiv
immun
deliveri
bnabencod
gene
gene
also
shown
effici
method
prevent
hiv
infect
human
mice
interest
see
strategi
translat
protect
human
hiv
balaz
et
al
quest
rsv
vaccin
met
mani
challeng
inspir
research
breakthrough
illustr
inform
human
immunolog
structur
biolog
studi
use
combin
instruct
vaccin
antigen
design
rsv
main
viral
caus
sever
respiratori
tract
diseas
children
worldwid
nair
et
al
also
afflict
elderli
immunocompromis
adult
falsey
et
al
membraneanchor
fusion
glycoprotein
f
present
surfac
viru
major
target
nab
anderson
et
al
howev
although
approv
therapeut
mab
treatment
palivizumab
target
f
exist
nearli
two
decad
impactrsv
studi
group
attempt
develop
rsv
vaccin
use
recombin
f
antigen
hamper
poor
behavior
solut
tendenc
undergo
larg
conform
chang
earli
epitopefocus
ration
antigen
design
enabl
cocryst
structur
fab
region
rsvneutral
mab
motavizumab
affinityenhanc
form
palivizumab
bound
target
f
epitop
prepar
synthet
peptid
adopt
helixturnhelix
motif
crystal
mclellan
et
al
howev
initi
attempt
design
immunogen
compris
scaffold
protein
present
f
epitop
observ
helixturnhelix
conform
partial
success
immun
conformationspecif
antif
ab
elicit
lack
abil
neutral
rsv
mclellan
et
al
subsequ
correia
et
al
report
proofofprincipl
studi
wherein
develop
new
structurebas
approach
comput
design
optim
improv
biophys
robust
scaffold
protein
display
desir
rsv
peptid
epitop
conform
faith
manner
abl
elicit
rsv
nab
nonhuman
primat
nhp
furthermor
rsv
peptid
epitop
scaffold
antigen
mount
multicopi
order
array
surfac
viruslik
particl
link
hepat
b
core
antigen
least
half
nhp
rais
rsvneutral
activ
compar
induc
natur
human
infect
thu
care
manipul
properli
present
structur
optim
form
singl
welldefin
protect
epitop
result
gener
desir
immun
respons
demonstr
feasibl
novel
immunefocus
approach
nevertheless
variabl
immun
respons
divers
human
popul
togeth
risk
emerg
natur
occur
epitop
escap
mutant
make
vaccin
approach
reli
singl
protect
epitop
potenti
less
robust
compar
immun
strategi
base
fulllength
antigen
entir
ectodomain
rsv
f
protein
would
potenti
offer
broader
immun
respons
trimer
f
protein
rsv
undergo
major
conform
chang
rel
compact
metast
prefus
state
elong
highli
stabl
postfus
state
mclellan
et
al
exposur
virion
surfac
prefus
structur
obviou
candid
vaccin
antigen
spontan
convers
recombin
prefus
f
postfus
state
discourag
initi
effort
direct
howev
although
engin
postfus
f
antigen
elicit
nab
anim
swanson
et
al
altern
studi
magro
et
al
use
immun
rabbit
sera
seroposit
human
sera
report
ab
target
prefus
f
protein
account
rsvneutral
activ
latter
highlight
import
renew
attempt
make
stabl
efficaci
prefus
f
antigen
facilit
discoveri
structur
character
new
mous
human
rsvneutral
mab
specif
prefus
f
crucial
cocryst
structur
report
mclellan
et
al
show
potent
rsvneutral
human
fab
bind
trap
f
previous
unobserv
prefus
conform
structur
reveal
larg
quaternari
epitop
prefus
f
trimer
apex
defin
major
site
vulner
novel
antigen
structur
subsequ
base
crystal
structur
mclellan
et
al
abl
stabil
prefus
f
antigen
trimer
conform
replac
transmembran
region
trimer
domain
insert
ad
hoc
mutat
creat
novel
disulfid
bridg
core
structur
improv
hydrophob
pack
new
prefus
antigen
abl
elicit
much
higher
level
rsvneutral
activ
compar
postfus
f
antigen
mous
nhp
model
although
polyinosin
polycytidyl
acid
adjuv
use
combin
engin
f
antigen
stimul
appropri
neutral
respons
inform
provid
regard
potenc
absenc
strong
adjuv
work
provid
eleg
preclin
demonstr
feasibl
structurebas
vaccin
strategi
driven
analysi
human
natur
protect
immun
respons
focus
mimicri
larg
conform
epitop
inde
studi
provid
hope
vaccin
contain
prefusionstabil
f
protein
would
induc
respons
protect
rsv
infect
human
clinic
trial
ongo
yet
anoth
import
area
human
immunolog
inform
design
novel
immunogen
search
broadli
protect
vaccin
antigen
protect
influenza
flu
persist
global
public
health
threat
lambert
fauci
tradit
flu
vaccin
made
use
ha
neuraminidas
antigen
purifi
egggrown
influenza
viru
efficaci
vaccin
antigen
genotyp
match
circul
strain
subtyp
howev
frequent
occurr
genet
variat
via
antigen
drift
reassort
impli
flu
vaccin
need
revis
annual
elicit
protect
respons
inde
bulk
immun
respons
trigger
either
vaccin
natur
infect
head
ha
highli
divers
distinct
strain
therefor
minim
crossprotect
one
strain
anoth
typic
achiev
consequ
flu
vaccin
effici
highli
variabl
depend
much
ha
circul
flu
strain
match
ha
vaccin
strain
moreov
present
avail
season
flu
vaccin
probabl
unabl
prevent
infect
new
emerg
strain
highli
pathogen
flu
viru
human
popul
previous
expos
strain
latter
circul
among
avian
popul
risk
zoonosi
human
may
trigger
deadli
pandem
infect
therefor
import
goal
develop
potent
univers
protect
flu
vaccin
gener
high
titer
bnab
influenza
viru
vaccin
ideal
induc
immun
respons
one
conserv
epitop
viral
protein
prevent
infect
diseas
nearli
possibl
circul
strain
flu
viru
ha
stem
region
inde
highli
conserv
among
differ
strain
subtyp
influenza
viru
region
poorli
immunogen
fulllength
ha
protein
contain
convent
vaccin
therefor
convent
flu
vaccin
abl
elicit
power
antistem
ha
ab
respons
howev
appropri
ha
stem
region
compon
univers
flu
vaccin
recent
confirm
find
bnab
region
ha
select
human
subject
infect
vaccin
kashyap
et
al
throsbi
et
al
ekiert
et
al
sui
et
al
corti
et
al
dreyfu
et
al
observ
driven
experiment
approach
aim
improv
immun
respons
stem
hai
et
al
schneemann
et
al
kanekiyo
et
al
aim
complic
rsv
f
see
rsv
section
nativ
ha
metast
membran
glycoprotein
undergo
larg
conform
chang
overcom
challeng
kanekiyo
et
al
use
structurebas
design
gener
genet
fusion
encod
ha
one
strain
link
bacteri
protein
ferritin
natur
oligomer
ferritin
polypeptid
spontan
selfassembl
nanoparticl
display
eight
trimer
subtyp
ha
spike
project
ferritin
nanoparticl
scaffold
orient
immun
system
could
encount
order
array
ha
nativelik
conform
test
preclin
vivo
model
eleg
multival
immunogen
present
structur
intact
ha
trimer
effect
elicit
higher
titer
nab
compar
similarli
adjuv
trival
inactiv
vaccin
tiv
mice
ferret
provid
broader
coverag
unmatch
virus
analysi
specif
immun
respons
reveal
nab
gener
nanoparticl
direct
sensit
receptor
bind
site
ha
head
conserv
ha
stem
region
latter
respons
half
observ
heterosubtyp
neutral
although
could
consid
real
univers
flu
vaccin
ha
vaccin
prove
potent
broad
neutral
respons
ha
stem
region
induc
use
appropri
immunogen
howev
potent
crossprotect
respons
observ
presenc
strong
adjuv
ribi
adjuv
may
work
improv
develop
follicular
helper
cell
germin
center
antigenspecif
b
cell
respons
mastel
gavillet
et
al
thu
help
select
lowabund
b
cell
clone
recogn
poorli
immunogen
epitop
ha
stem
region
experiment
prove
model
antigen
victora
et
al
identif
human
mab
abl
bind
conserv
epitop
ha
stem
region
sever
flu
strain
belong
differ
subtyp
consid
first
step
toward
discoveri
ideal
immunogen
univers
flu
vaccin
ab
preciou
tool
use
cocryst
structur
studi
precis
identifi
neutral
epitop
ha
stem
region
bind
assay
isol
appropri
immunogen
induc
broad
protect
two
differ
group
recent
taken
advantag
stem
ab
cognat
structur
deriv
epitop
map
inform
ration
design
screen
seri
novel
immunogen
lead
select
stabl
immunogen
contain
appropri
conform
epitop
ha
stem
impagliazzo
et
al
yassin
et
al
team
led
nabel
graham
taken
advantag
ferritin
nanoparticl
present
refin
ha
antigen
compris
stemonli
immunogen
ration
design
stabil
trimer
headless
state
yassin
et
al
studi
design
strategi
driven
prior
human
immunolog
studi
detail
structur
knowledg
show
immunogen
subdomin
stem
region
ha
contain
highli
conserv
protect
conform
epitop
recogn
human
mab
multisubtyp
ha
recognit
profil
broader
target
variabl
head
region
throsbi
et
al
ekiert
et
al
sui
et
al
corti
et
al
dreyfu
et
al
friesen
et
al
new
structur
studi
xray
crystallographi
cryoelectron
microscopi
inform
iter
design
pathway
result
seven
gener
subtyp
hastabil
stem
immunogen
term
last
design
form
present
desir
trimer
structur
epitop
recogn
broadli
neutral
human
mab
recombin
antigen
fuse
ferritin
assembl
nanoparticl
surfac
term
confirm
possess
desir
antigen
featur
importantli
preclin
immun
studi
induc
higher
ab
respons
ha
stem
compar
classic
trival
inactiv
flu
vaccin
crossreact
mani
strain
also
distant
subtyp
group
group
although
neutral
could
observ
homolog
two
heterolog
strain
vaccin
result
complet
protect
mice
partial
protect
ferret
lethal
viral
challeng
use
heterosubtyp
latter
find
support
passiv
transfer
immunoglobulin
immun
mice
protect
naiv
mice
challeng
yassin
et
al
suggest
stem
ab
protect
effect
via
differ
mechan
viru
neutral
altern
rout
toward
goal
report
impagliazzo
et
al
use
ingeni
structurebas
design
method
combin
librari
approach
gener
minim
size
trimer
ha
immunogen
term
miniha
solubl
conform
stabl
satisfi
prerequisit
structur
antigen
mimic
highli
conserv
stem
region
fulllength
ha
reveal
capac
bind
stem
bnab
impagliazzo
et
al
describ
lead
candid
miniha
rais
broad
protect
immun
respons
complet
protect
mice
lethal
heterolog
heterosubtyp
challeng
model
furthermor
nhp
model
compar
tiv
immunogen
elicit
higher
ab
titer
homolog
well
varieti
heterolog
heterosubtyp
strain
bound
ha
stemneutr
epitop
trigger
potent
abdepend
cellular
cytotox
activ
abl
neutral
heterosubtyp
strain
howev
capac
lead
miniha
candid
reduc
fever
nhp
subleth
challeng
heterolog
strain
compar
tiv
wherea
reduct
tracheal
viral
load
could
observ
anim
leav
doubt
superior
novel
vaccin
anim
model
thu
potenti
univers
flu
vaccin
human
nevertheless
small
hastem
construct
consid
good
start
point
vaccin
candid
rais
broadli
protect
immun
respons
group
flu
virus
may
extend
group
final
note
structur
design
miniha
describ
previou
paragraph
report
elicit
broadli
reactiv
ab
ha
stem
administ
presenc
ribi
matrix
respect
studi
appear
suggest
strong
adjuv
may
requir
obtain
appropri
respons
conserv
subdomin
epitop
ha
stem
region
like
act
enhanc
follicular
helper
cell
germin
center
therefor
drive
select
scarc
b
cell
specif
epitop
collect
studi
fine
demonstr
structurebas
antigen
design
use
obtain
improv
immun
respons
specif
direct
toward
target
epitop
identifi
human
immunolog
studi
valid
structur
biolog
studi
clinic
studi
human
requir
fulli
demonstr
power
synergist
approach
anoth
great
advanc
knowledg
human
immun
respons
pathogen
aid
design
new
efficaci
vaccin
come
possibl
obtain
detail
overview
ab
repertoir
gener
infect
analysi
appli
hivinfect
individu
reveal
rare
natur
occur
antienv
bnab
character
larg
number
somat
mutat
aris
multipl
round
select
respons
emerg
escap
mutant
hiv
env
glycoprotein
mouquet
et
al
surprisingli
found
germlin
ab
precursor
hiv
bnab
low
affin
nativ
heterolog
env
variant
observ
suggest
immunogen
base
natur
env
ineffici
expand
right
germlin
b
cell
clone
unabl
elicit
crossneutr
ab
xiao
et
al
liao
et
al
doriaros
et
al
therefor
altern
stepwis
vaccin
strategi
recent
propos
base
prime
engin
antigen
design
target
germlin
precursor
hiv
bnab
follow
sequenti
boost
seri
intermedi
antigen
would
progress
match
conform
natur
env
protein
although
complet
demonstr
valid
germlinetarget
vaccin
approach
achiev
yet
promis
support
data
publish
recent
month
previous
shown
group
hiv
crossneutr
ab
differ
donor
collect
call
class
ab
target
hiv
env
deriv
germlin
variabl
heavi
chain
variabl
light
chain
character
short
five
amino
acid
jardin
et
al
report
use
multipl
round
comput
design
structur
analysi
engin
extern
outer
domain
eod
env
protein
abl
bind
germlin
precursor
ab
high
affin
select
protein
fuse
linker
bacteri
lumazin
synthas
allow
format
viruslik
protein
nanoparticl
abl
activ
b
cell
express
either
matur
b
cell
receptor
germlin
precursor
recent
improv
version
multimer
germlinetarget
antigen
use
two
independ
studi
immun
knockin
mice
human
variabl
heavi
chain
dosenov
et
al
jardin
et
al
studi
shown
abl
expand
b
cell
express
human
transgen
heavi
chain
combin
mous
light
chain
resembl
natur
occur
light
chain
human
introduc
seri
somat
mutat
gene
similar
observ
natur
occur
hiv
bnab
contrast
nativ
env
trimer
unabl
expand
b
cell
knockin
mice
importantli
studi
ab
gener
immun
although
similar
abl
neutral
hiv
infect
studi
dosenov
et
al
env
trimer
also
use
immun
differ
knockin
mous
strain
express
matur
heavi
chain
human
nab
contain
natur
rais
somat
mutat
would
pair
naiv
chain
mous
repertoir
mous
strain
effici
trigger
nab
respons
wherea
env
trimer
trigger
robust
crossneutr
ab
respons
select
appropri
mous
light
chain
data
gener
far
demonstr
possibl
gener
hiv
broadli
crossneutr
ab
use
germlin
target
antigen
howev
suggest
germlin
target
antigen
use
prime
naiv
b
cell
encod
germlin
precursor
hiv
bnab
nativelik
hiv
env
antigen
requir
select
expand
b
cell
express
crossneutr
ab
consequ
somat
hypermut
process
addit
work
use
multipl
intermedi
env
antigen
requir
obtain
definit
proof
concept
feasibl
germlinetarget
vaccin
approach
recent
technolog
advanc
human
immunolog
structur
biolog
provid
new
reagent
improv
tool
allow
better
understand
basic
biolog
molecular
mechan
lead
protect
human
immun
respons
pathogen
inspir
new
strategi
vaccin
design
approach
eg
stabil
rsv
prefus
f
antigen
discoveri
hcmv
pentam
complex
solid
preclin
proof
principl
obtain
support
clinic
develop
howev
addit
preclin
work
still
requir
demonstr
valid
ration
design
vaccin
eg
univers
flu
hiv
antigen
nevertheless
investig
basic
mechan
regul
human
immun
respons
pathogen
continu
facilit
design
new
efficaci
vaccin
infecti
diseas
combin
applic
describ
new
tool
human
immunolog
structur
biolog
microbi
genom
establish
new
multidisciplinari
approach
vaccin
antigen
discoveri
design
may
term
revers
vaccinolog
